Changes in high-density lipoprotein and homeostasis model assessment of insulin resistance in medicated schizophrenic patients and healthy controls

Chang Gung Medical Journal

Volumn 33, Issue 6, 2010, Pages 613-618

  Tsai, Meng Chang ^a   Chang, Chia Ming ^a   Huang, Tiao Lai ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

High density lipoprotein (HDL); HOMA IR; Insulin; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; BIOLOGICAL MARKER; CHOLESTEROL; FLUPENTIXOL; GLUCOSE; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; RISPERIDONE; SULPIRIDE; TRIACYLGLYCEROL; ZIPRASIDONE;

ADULT; ANALYSIS OF COVARIANCE; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; ENZYME ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; MALE; POSTPRANDIAL STATE; SCHIZOPHRENIA; SIDE EFFECT; TAIWAN; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; FEMALE; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; LIPOPROTEINS, HDL; MALE; SCHIZOPHRENIA;

EID: 78651245503     PISSN: 20720939     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Henderson DC. Schizophrenia and comorbid metabolic disorders. J Clin Psychiatry 2005;66 Suppl 6:11-20.
2. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006;17:4-12.
3. Yan E, Chen S, Hong K, Kim WS, Bajpai A, Treyzon L, Gratton L, Elashoff R, Wang HJ, Li Z, Heber D. Insulin, hs-CRP, leptin, and adiponectin. An analysis of their relationship to the metabolic syndrome in an obese population with an elevated waist circumference. Metab Syndr Relat Disord 2008;6:64-73.
4. Ukkola O. Ghrelin and metabolic disorders. Curr Protein Pept Sci 2009;10:2-7.
5. van Kammen DP, McAllister-Sistilli CG, Kelley ME, Gurklis JA, Yao JK. Elevated interleukin-6 in schizophrenia. Psychiatry Res 1999;87:129-36.
6. Tan JT, McLennan SV, Song WW, Lo LW, Bonner JG, Williams PF, Twigg SM. Connective tissue growth factor inhibits adipocyte differentiation. Am J Physiol Cell Physiol 2008;295:C740-51.
7. Fain JN, Tichansky DS, Madan AK. Transforming growth factor beta1 release by human adipose tissue is enhanced in obesity. Metabolism 2005;54:1546-51.
8. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004;70:1-17.
9. Huang TL, Chen JF. Serum lipid profiles and schizophrenia: effects of conventional or atypical antipsychotic drugs in Taiwan. Schizophr Res 2005;80:55-9.
10. Tschoner A, Engl J, Rettenbacher M, Edlinger M, Kaser S, Tatarczyk T, Effenberger M, Patsch JR, Fleischhacker WW, Ebenbichler CF. Effects of six second generation antipsychotics on body weight and metabolism - risk assessment and results from a prospective study. Pharmacopsychiatry 2009;42:29-34.
11. Popovic V, Doknic M, Maric N, Pekic S, Damjanovic A, Miljic D, Popovic S, Miljic N, Djurovic M, Jasovic-Gasic M, Dieguez C, Casanueva FF. Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia. Neuroendocrinology 2007;85:249-56.
12. Melkersson KI, Scordo MG, Gunes A, Dahl ML. Impact of CYP1A2 and CYP2D6 polymorphisms on drug metabolism and on insulin and lipid elevations and insulin resistance in clozapine-treated patients. J Clin Psychiatry 2007;68:697-704.
13. Sicras-Mainar A, Blanca-Tamayo M, Rejas-Gutiérrez J, Navarro-Artieda R. Metabolic syndrome in outpatients receiving antipsychotic therapy in routine clinical practice: a cross-sectional assessment of a primary health care database. Eur Psychiatry 2008;23:100-8.
14. Duncan EJ, Woolson SL, Hamer RM, Dunlop BW. Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans Affairs population. Int Clin Psychopharmacol 2009;24:204-13.
15. Reaven GM, Lieberman JA, Sethuraman G, Kraemer H, Davis JM, Blasey C, Tsuang MT, Schatzberg AF. In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment. J Psychiatr Res 2009;43:997-1002.
16. Rabe-Jabónska J, Paweczyk T. The metabolic syndrome and its components in participants of EUFEST. Psychiatr Pol 2008;42:73-85.
17. Casey DE. Dyslipidemia and atypical antipsychotic drugs. J Clin Psychiatry 2004;65 Suppl 18:27-35.
18. Birkenaes AB, Birkeland KI, Engh JA, Faerden A, Jonsdottir H, Ringen PA, Friis S, Opjordsmoen S, Andreassen OA. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. J Clin Psychopharmacol 2008;28:132-7.
19. Verma SK, Subramaniam M, Liew A, Poon LY. Metabolic risk factors in drug-naive patients with first-episode psychosis. J Clin Psychiatry 2009;70:997-1000.
20. Yamamoto K, Fukuda M, Nogawa A, Takahashi E, Miyaoka H. Decreased lipoprotein lipase as a risk factor for atypical neuroleptic-induced hypertriglyceridemia. J Clin Psychiatry 2007;68:802.
21. Reddymasu S, Bahta E, Levine S, Manas K, Slay LE. Elevated lipase and diabetic ketoacidosis associated with aripiprazole. JOP 2006;7:303-5.
22. Ghio L, Fornaro G, Rossi P. Risperidone-induced hyperamylasemia, hyperlipasemia, and neuroleptic malignant syndrome: a case report. J Clin Psychopharmacol 2009;29:391-2.
23. Stahl SM, Mignon L, Meyer JM. Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta Psychiatr Scand 2009;119:171-9.
24. Elias AN, Hofflich H. Abnormalities in glucose metabolism in patients with schizophrenia treated with atypical antipsychotic medications. Am J Med 2008;121:98-104.
25. Sengupta S, Parrilla-Escobar MA, Klink R, Fathalli F, Ying Kin Ng, Stip E, Baptista T, Malla A, Joober R. Are metabolic indices different between drug-naïve firstepisode psychosis patients and healthy controls? Schizophr Res 2008;102:329-36.
26. Venkatasubramanian G, Chittiprol S, Neelakantachar N, Naveen MN, Thirthall J, Gangadhar BN, Shetty KT. Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia. Am J Psychiatry 2007;164:1557-60.
27. Fairuz AR, Maniam T, Khalid BA. Prevalence of insulin resistance in schizophrenia in HUKM. Med J Malaysia 2007;62:290-3.
28. Wu MK, Huang CY, Liou YJ, Wang CK, Lee SD. Glucose-insulin homeostasis, lipid profiles and GH-IGFIGFBP axis in clozapine-treated schizophrenic obesity versus non-psychiatric obesity. Int J Obes (Lond) 2008;32:436-42.
29. Ebenbichler CF, Laimer M, Eder U, Mangweth B, Weiss E, Hofer A, Hummer M, Kemmler G, Lechleitner M, Patsch JR, Fleischhacker WW. Olanzapine induces insulin resistance: results from a prospective study. J Clin Psychiatry 2003;64:1436-9.
30. Henderson DC, Copeland PM, Borba CP, Daley TB, Nguyen DD, Cagliero E, Evins AE, Zhang H, Hayden DL, Freudenreich O, Cather C, Schoenfeld DA, Goff DC. Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. J Clin Psychiatry 2006;67:789-97.